Introduction {#sec1-2055217319828400}
============

Among the recognized environmental risk factors for multiple sclerosis (MS), the most evidence has been acquired for low vitamin D levels, low of exposure to ultraviolet light, Epstein--Barr virus, and, importantly, cigarette smoking.^[@bibr1-2055217319828400],[@bibr2-2055217319828400]^ As the incidence of MS rose consistently during the 20th century, cigarette smoking became a widespread habit in the general population in Europe and North America. Since the 1960s, epidemiological studies identified cigarette smoking as a risk factor for MS. Smoking has been associated with a dose dependent increased susceptibility to MS and, to a lesser extent, with the risk of conversion from clinically isolated syndrome (CIS) to clinically definite MS, and with an increased susceptibility to secondary progressive MS conversion.^[@bibr3-2055217319828400][@bibr4-2055217319828400][@bibr5-2055217319828400][@bibr6-2055217319828400][@bibr7-2055217319828400]--[@bibr8-2055217319828400]^ MS patients who smoke also seem to be predisposed to faster rates of disability accrual, as shown by higher Expanded Disability Status Scale (EDSS) scores.^[@bibr3-2055217319828400],[@bibr5-2055217319828400],[@bibr9-2055217319828400][@bibr10-2055217319828400]--[@bibr11-2055217319828400]^

The impact of smoking in MS patients has also been assessed through imaging studies: on magnetic resonance imaging, smokers show greater lesion volumes, higher brain T2 lesion loads, and more severe brain atrophy than non-smokers.^[@bibr4-2055217319828400],[@bibr5-2055217319828400]^ Spectral-domain optical coherence tomography (OCT) measurement of the retina yields high resolution imaging and quantification of the peripapillary retinal nerve fiber layer (RNFL) and segmented macular layers. RNFL and ganglion cell-inner plexiform layer (GCIP) have been used as outcome measures in a wide variety of studies: both appear to correlate with visual function and global disability (EDSS). In particular, GCIP appears to correlate with brain T2 lesion load, brain atrophy and EDSS-measured disability progression, rendering it a more robust measure than RNFL as it is less prone to artifacts and in the acute setting is less affected by post-optic neuritis associated swelling. The correlation between brain and retinal atrophy seems to result from a pathology of anterior visual pathway: while retrograde neurodegeneration results in GCIP thinning, anterograde neurodegeneration results in brain atrophy.^[@bibr12-2055217319828400][@bibr13-2055217319828400][@bibr14-2055217319828400][@bibr15-2055217319828400]--[@bibr16-2055217319828400]^ Pathology studies have shown that anterior visual pathway damage is common among MS patients and therefore, it is a good hallmark of overall MS-related neurodegeneration.^[@bibr17-2055217319828400]^

We utilized OCT in an attempt to examine the impact of cigarette smoking on retinal measures in MS patients. To better characterize our population, we stratified out patients according to their smoking history (ever-smokers vs. never-smokers).

Materials and methods {#sec2-2055217319828400}
=====================

Subjects {#sec3-2055217319828400}
--------

Subjects enrolled in the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital (CLIMB) who also met the further inclusion criteria for this cross-sectional analysis: (1) enrolled in the longitudinal OCT subgroup, (2) were over the age of 18, and (3) met the 2010 McDonald diagnostic criteria for MS or CIS. As part of the demographic survey, patients provided both basic personal data such as gender, date of birth, optic neuritis (ON) history, and smoking history categorized as being never-smokers or ever-smokers. When providing ON history, each patient was asked to include the dates of past ON event and the laterality of each ON episode (bilateral, left, right). Healthy control (HC) subjects were also included and provided basic demographic data. All the data was then stored on the internal relational database of the CLIMB study. Exclusion criteria for MS and HC subjects included previous history of ophthalmological disorders, e.g., clinically-significant cataracts, glaucoma, diabetes and/or diabetic retinopathy, macular degeneration, and retinal detachment; refractive errors exceeding ±6 diopters; history of immunological and/or neurological disorders such as neuromyelitis optica, systemic lupus erythematosus, asthma, autoimmune thyroiditis, and rheumatoid arthritis. Additionally, we excluded from the study all MS patients with an acute use of steroids or acute ON within three months of OCT scans. Ten MS patients were excluded from the primary analysis due to their unknown status for smoking history.

All MS patients underwent standardized clinical exams performed by a neurologist, and OCT scanning. HCs also underwent visual acuity testing, and OCT scanning. Visual acuity was assessed for one eye at a time while the non-tested fellow eye was covered by the patient. The score of each chart was based on the number of letters correctly identified, which ranged from 0 to 60. Each patient was examined under reproducible conditions: the distance from the chart, the lighting of the room, and the test instructions were standardized. Also, all study participants provided written informed consent for their participation and the Partners Human Research Committee provided Institutional Review Board (IRB) approval.

Optical coherence tomography {#sec4-2055217319828400}
----------------------------

Retinal imaging was performed by trained examiners using Spectralis OCT (software version 6.0.9.0, Heidelberg Engineering, Heidelberg, Germany). Peripapillary RNFL and macular volume scans were obtained from both eyes of each participant (without dilation), with automated segmentation providing measures of the GCIP. Scans were obtained using high resolution and automatic real-time tracking for B-scan averaging to enhance quality and were subsequently manually inspected to corroborate accurate fixation and centering.

Statistical analysis {#sec5-2055217319828400}
--------------------

We compared the demographic and clinical characteristics between ever-smoker and never-smoker MS patients at the baseline OCT exam. The continuous variables were described by mean and standard deviation (SD), while the categorical variables were described by counts and percentages. Means were compared with either a two-sample t-test or a Mann--Whitney U test for non-normal data, while proportions were compared with either a chi-square test or Fisher's exact test for contingency tables.

We then compared RNFL and GCIP measurements between MS patients and HC. Since both eyes of each subject were included in this analysis, linear mixed models with unstructured correlation structures were used to adjust for the within-subject correlation. Multivariable linear mixed effects regression model assessed differences in RNFL and GCIP measurements with fixed effects for MS versus HC while adjusting for ON eye status, age, and sex.

We assessed the relationship of RNFL and GCIP measurements between ever-smokers and never-smokers using mixed linear regression models. Multivariable linear mixed effects regression model with unstructured correlation structures assessed differences in RNFL and GCIP measurements with fixed effects for smoking history while adjusting for ON eye status, age, disease duration, sex, baseline EDSS, and disease modifying therapies (DMTs). All statistical analyses were performed using SAS version 9.4 (Statistical Analytical System, SAS Institute).

Results {#sec6-2055217319828400}
=======

Demographics {#sec7-2055217319828400}
------------

Out of 112 MS patients, 102 had information available on cigarette smoking. 46 (45.10%) were ever-smokers and 56 (54.90%) were never-smokers. [Table 1](#table1-2055217319828400){ref-type="table"} displays demographic and baseline clinical characteristics of MS patients grouped according to their smoking status. Ever-smoker patients had longer disease duration at visit (17 vs. 12 years, *p* = 0.0038) and higher EDSS at visit (3 vs. 2, *p* = 0.0017) than never-smokers. There was no statistically significant difference in terms of their age at the baseline visit (48 vs. 45, *p* = 0.1540) or in their history of ON (54% vs. 43%, *p* = 0.2478).

###### 

Demographics characteristics between ever-smokers versus never-smokers MS patients.

![](10.1177_2055217319828400-table1)

  Variables                                      Ever-smokers    Never-smokers   *p*-value
  ---------------------------------------------- --------------- --------------- -----------
  *N*                                            46              56              
  Optic neuritis, *n*(%)                                                         0.2478^b^
   Yes                                           25 (54.35%)     24 (42.86%)     
   No                                            21 (45.65%)     32 (57.14%)     
  Sex, *n*(%)                                                                    0.5042^b^
   Female                                        34 (73.91%)     38 (67.86%)     
   Male                                          12 (26.09%)     18 (32.14%)     
  Age at OCT exam date, years (mean ± SD)        47.92 ± 9.08    45.39 ± 8.64    0.1540^a^
  Race, *n* (%)                                                                  0.5985^c^
   Native American or Alaska Native              0 (0.00%)       1 (1.79%)       
   Black or African American                     1 (2.17%)       2 (3.57%)       
   More than one race                            0 (0.00%)       1 (1.79%)       
   White                                         45 (97.83%)     52 (92.86%)     
  Ethnicity, *n* (%)                                                             0.6249^c^
   Hispanic or Latino                            1 (2.17%)       3 (5.36%)       
   Not Hispanic or Latino                        45 (97.83%)     52 (92.86%)     
   Unknown or not reported                       0 (0.00%)       1 (1.79%)       
  Age at first symptom, years (mean ± SD)        30.89 ± 11.09   33.45 ± 8.61    0.1916^a^
  Disease duration at visit, years (mean ± SD)   17.02 ± 10.23   11.93 ± 7.06    0.0038^a^
  EDSS at visit, (mean ± SD)                     3.36 ± 2.26     2.04 ± 1.51     0.0017^d^
  Disease category, *n* (%)                                                      0.1492^c^
   CIS                                           3 (6.52%)       2 (3.57%)       
   Primary progressive MS                        2 (4.35%)       1 (1.79%)       
   Secondary progressive MS                      10 (21.74%)     5 (8.93%)       
   Relapsing--remitting MS                       31 (67.39%)     48 (85.71%)     
  DMT                                                                            0.6740^c^
   Aubagio                                       1 (2.17%)       0 (0.00%)       
   Avonex                                        3 (6.52%)       4 (7.14%)       
   Betaseron                                     1 (2.17%)       2 (3.57%)       
   Cellcept                                      5 (10.87%)      2 (3.57%)       
   Copaxone                                      5 (10.87%)      13 (23.21%)     
   Gilenya                                       8 (17.39%)      10 (17.86%)     
   Imuran                                        8 (17.39%)      8 (14.29%)      
   None                                          2 (4.35%)       1 (1.79%)       
   Rebif                                         1 (2.17%)       0 (0.00%)       
   Rituxan                                       6 (13.04%)      8 (14.29%)      
   Tecfidera (BG-12)                             6 (13.04%)      8 (14.29%)      
   Tysabri                                       1 (2.17%)       0 (0.00%)       

MS = multiple sclerosis; OCT = optic coherence tomography; EDSS = Expanded Disability Status Scale; CIS = clinically isolated syndrome; SD = standard deviation.

Means were compared with a two-sample t-test.

Proportions were compared via a chi-square test for contingency tables.

Proportions were compared via a Fisher's exact test for contingency tables.

Rank scores were compared via the Mann--Whitney U test.

MS and healthy controls {#sec8-2055217319828400}
-----------------------

57 HC and 112 MS patients were included in our preliminary analysis which focused on comparing the two groups in RNFL and GCIP measures. Supplementary table 1 shows their baseline demographic and clinical characteristics. HC were younger (38 y.o. vs. 46 y.o., *p* \< 0.0001) and more racially diverse (*p* \< 0.0001) compared to MS patients.

As expected, MS patients had lower retinal thickness compared to HC. MS patients had lower total macular volume compared to HC (HC: 1.94 mm^3^ vs. MS: 1.77 mm^3^, β = 0.11, *p* = 0.0106), lower GCIP inner ring thickness (HC: 93.36 µm vs. MS: .26 µm, β = 11.81, *p* \< 0.0001), and thinner GCIP outcomes across all individual quadrants ([Table 2](#table2-2055217319828400){ref-type="table"}). HC had greater mean global RNFL (99.62 µm vs. 85.99 µm, β = 12.14, *p* \< 0.0001) and greater RNFL papillomacular bundle (PMB) thickness (58.16 µm vs. 48.19 µm, β = 8.40, *p* = 0.0015) compared to MS patients ([Table 3](#table3-2055217319828400){ref-type="table"}).

###### 

Association of GCIP measurements between MS patients versus healthy controls.

![](10.1177_2055217319828400-table2)

  GCIP                               MS    HC              Adjusted estimate^[a](#table-fn7-2055217319828400){ref-type="table-fn"}^   Adjusted *p*-value^[a](#table-fn7-2055217319828400){ref-type="table-fn"}^            
  ---------------------------------- ----- --------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------- -------- ---------
  Total macular volume (mm^3^)       220   1.77  ±  0.26   114                                                                        1.94 ± 0.28                                                                 0.11     0.0106
  Mean central GCIP thickness (μm)   220   45.07 ± 13.95   111                                                                        38.44 ± 8.96                                                                −7.85    0.0003
  Mean GCIP N1 thickness (μm)        220   83.07 ± 16.43   111                                                                        94.15 ± 9.84                                                                6.61     0.0044
  Mean GCIP N2 thickness (μm)        220   59.54 ± 9.10    110                                                                        68.88 ± 6.43                                                                8.34     \<.0001
  Mean GCIP S1 thickness (μm)        219   80.64 ± 14.32   111                                                                        94.92 ± 7.16                                                                11.00    \<.0001
  Mean GCIP S2 thickness (μm)        219   54.21 ± 8.05    111                                                                        62.48 ± 5.31                                                                7.07     \<.0001
  Mean GCIP T1 thickness (μm)        220   79.48 ± 15.39   111                                                                        90.79 ± 8.30                                                                7.45     0.0007
  Mean GCIP T2 thickness (μm)        218   61.41 ± 8.37    111                                                                        67.26 ± 5.38                                                                8.34     \<.0001
  Mean GCIP I1 thickness (μm)        220   77.40 ± 16.62   111                                                                        93.58 ± 8.84                                                                11.81    \<.0001
  Mean GCIP I2 thickness (μm)        219   58.79 ± 8.14    111                                                                        59.50 ± 6.15                                                                0.06     0.9644
  Center thickness (μm)              220   30.56 ± 19.24   111                                                                        15.53 ± 5.10                                                                −14.37   \<.0001
  Central minimal thickness (μm)     220   13.05 ± 3.22    111                                                                        12.05 ± 3.09                                                                −0.70    0.1769
  Central maximal thickness (μm)     220   82.88 ± 19.92   111                                                                        78.61 ± 14.84                                                               −8.53    0.0045
  Inner ring thickness (μm)          219   80.26 ± 14.94   111                                                                        93.36 ± 7.95                                                                11.81    \<.0001

MS = multiple sclerosis; HC = healthy control; GCIP = ganglion cell-inner plexiform; SD = standard deviation.

Multivariable linear mixed effects model adjusted for age and sex.

###### 

Association of RNFL measurements between MS patients versus healthy control.

![](10.1177_2055217319828400-table3)

  RNFL                              MS    HC              Adjusted estimate^[a](#table-fn9-2055217319828400){ref-type="table-fn"}^   Adjusted *p*-value^[a](#table-fn9-2055217319828400){ref-type="table-fn"}^           
  --------------------------------- ----- --------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------- ------- ---------
  Mean global RNFL thickness (μm)   197   85.99 ± 14.16   108                                                                        99.62 ± 10.38                                                               12.14   \<.0001
  Mean RNFL thickness, PMB (μm)     207   48.19 ± 15.45   111                                                                        58.16 ± 14.64                                                               8.36    0.0015
  N/T RNFL thickness ratio          196   1.15 ± 0.38     107                                                                        1.11 ± 0.51                                                                 0.02    0.7458
  Mean RNFL thickness, NS (μm)      200   92.06 ± 22.80   110                                                                        104.4 ± 25.65                                                               11.89   0.0018
  Mean RNFL thickness, N (μm)       197   66.58 ± 18.16   107                                                                        75.90 ± 21.94                                                               9.38    0.0038
  Mean RNFL thickness, NI (μm)      202   103.3 ± 25.71   110                                                                        115.5 ± 26.73                                                               11.62   0.0078
  Mean RNFL thickness, TI (μm)      204   122.2 ± 26.18   109                                                                        139.9 ± 22.30                                                               11.35   0.0046
  Mean RNFL thickness, T (μm)       207   61.37 ± 17.71   111                                                                        74.92 ± 19.01                                                               10.80   0.0003
  Mean RNFL thickness, TS (μm)      205   116.2 ± 22.68   109                                                                        131.2 ± 21.89                                                               12.75   0.0006

MS = multiple sclerosis; HC = healthy control; RNFL = retinal nerve fiber layer; PMB = papillomacular bundle thickness; SD = standard deviation.

Multivariable linear mixed effects model adjusted for age and sex.

Relationship of smoking history to GCIP and RNFL {#sec9-2055217319828400}
------------------------------------------------

We tested the association of GCIP and RNFL measurements between ever-smokers versus never-smokers MS patients, including nine RNFL and fourteen GCIP sectors ([Tables 4](#table4-2055217319828400){ref-type="table"} and [5](#table5-2055217319828400){ref-type="table"}). We failed to find any significant effect on GCIP metrics or RNFL measurements between ever-smokers versus never-smokers MS patients after adjusting for ON eye status, age, disease duration, sex, baseline EDSS and DMTs. The distribution in GCIP total macular volume, GCIP inner ring thickness, RNFL mean global, and RNFL PMB between ever-smokers and never-smokers are shown in [Figure 1](#fig1-2055217319828400){ref-type="fig"}.

![Comparing RNFL and GCIP distributions between the ever-smokers versus never-smokers showing the median, mean (unfilled diamond shape), and interquartile range. (a) Comparing GCIP total macular volume between ever-smokers (*N* = 45) vs. never-smokers (*N* = 60). (b) Comparing GCIP inner ring thickness between ever-smokers (*N* = 44) vs. never-smokers (*N* = 60). (c) Comparing RNFL mean global thickness between ever-smokers (*N* = 40) vs. never-smokers (*N* = 49). (d) Comparing RNFL mean thickness PMB between ever-smokers (*N* = 41) vs. never-smokers (*N* = 53).](10.1177_2055217319828400-fig1){#fig1-2055217319828400}

###### 

Association of GCIP measurements between ever-smokers versus never-smokers MS patients.

![](10.1177_2055217319828400-table4)

  GCIP                               Ever-smokers   Never-smokers   Adjusted estimate^[a](#table-fn11-2055217319828400){ref-type="table-fn"}^   Adjusted *p*-value^[a](#table-fn11-2055217319828400){ref-type="table-fn"}^           
  ---------------------------------- -------------- --------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------- --------
  Total macular volume (mm^3^)       89             1.76 ± 0.27     111                                                                         1.79 ± 0.24                                                                  0.02    0.6912
  Mean central GCIP thickness (μm)   89             45.66 ± 13.62   111                                                                         45.03 ± 13.62                                                                −0.44   0.8718
  Mean GCIP N1 thickness (μm)        89             82.39 ± 16.22   111                                                                         83.69 ± 15.36                                                                2.91    0.3078
  Mean GCIP N2 thickness (μm)        89             58.84 ± 9.45    111                                                                         60.04 ± 8.60                                                                 0.46    0.7963
  Mean GCIP S1 thickness (μm)        88             79.93 ± 15.03   111                                                                         81.47 ± 12.94                                                                2.46    0.3569
  Mean GCIP S2 thickness (μm)        88             53.36 ± 8.85    111                                                                         55.04 ± 7.36                                                                 0.47    0.7814
  Mean GCIP T1 thickness (μm)        89             79.02 ± 15.30   111                                                                         79.95 ± 14.95                                                                2.91    0.2941
  Mean GCIP T2 thickness (μm)        89             60.84 ± 9.37    109                                                                         62.01 ± 7.28                                                                 0.11    0.9479
  Mean GCIP I1 thickness (μm)        89             75.99 ± 17.82   111                                                                         78.36 ± 14.80                                                                2.41    0.4380
  Mean GCIP I2 thickness (μm)        89             58.66 ± 7.91    110                                                                         59.16 ± 7.92                                                                 −0.81   0.6195
  Center thickness (μm)              89             32.03 ± 20.03   111                                                                         29.97 ± 18.48                                                                −1.81   0.6436
  Central minimal thickness (μm)     89             12.88 ± 3.83    111                                                                         13.36 ± 2.66                                                                 −1.01   0.1157
  Central maximal thickness (μm)     89             84.53 ± 18.46   111                                                                         82.65 ± 19.27                                                                2.96    0.4205
  Inner ring thickness (μm)          88             79.60 ± 15.23   111                                                                         80.87 ± 13.82                                                                3.11    0.2504

MS = multiple sclerosis; GCIP = ganglion cell-inner plexiform; SD = standard deviation.

Multivariable linear mixed effects model adjusted for ON eye status, age, disease duration, sex, baseline EDSS, and DMT.

###### 

Association of RNFL measurements between ever-smokers versus never-smokers MS patients.

![](10.1177_2055217319828400-table5)

  RNFL                              Ever-smokers   Never-smokers   Adjusted estimate^[a](#table-fn13-2055217319828400){ref-type="table-fn"}^   Adjusted *p*-value^[a](#table-fn13-2055217319828400){ref-type="table-fn"}^           
  --------------------------------- -------------- --------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------- --------
  Mean global RNFL thickness (μm)   80             86.25 ± 14.19   97                                                                          85.56 ± 14.07                                                                1.97    0.4937
  Mean RNFL thickness, PMB (μm)     82             47.01 ± 12.59   105                                                                         49.12 ± 17.63                                                                −2.53   0.4620
  N/T RNFL thickness ratio          80             1.18 ± 0.36     96                                                                          1.11 ± 0.38                                                                  0.05    0.4698
  Mean RNFL thickness, NS (μm)      83             92.52 ± 21.93   97                                                                          91.30 ± 23.75                                                                4.08    0.3536
  Mean RNFL thickness, N (μm)       81             69.02 ± 20.87   96                                                                          64.47 ± 15.35                                                                6.82    0.0530
  Mean RNFL thickness, NI (μm)      80             103.4 ± 22.25   103                                                                         102.5 ± 28.77                                                                1.80    0.7393
  Mean RNFL thickness, TI (μm)      81             122.2 ± 27.08   103                                                                         122.4 ± 24.99                                                                0.81    0.8661
  Mean RNFL thickness, T (μm)       82             60.55 ± 17.21   105                                                                         62.03 ± 18.19                                                                −1.05   0.7709
  Mean RNFL thickness, TS (μm)      83             116.8 ± 23.08   102                                                                         114.2 ± 21.70                                                                6.41    0.1393

MS = multiple sclerosis; RNFL = retinal nerve fiber layer; PMB = papillomacular bundle thickness; SD = standard deviation.

Multivariable linear mixed effects model adjusted for ON eye status, age, disease duration, sex, baseline EDSS, and DMT.

Discussion {#sec10-2055217319828400}
==========

In this cross-sectional study, our aim was to determine whether or not a history of cigarette smoking was associated with retinal damage quantified by RNFL, GCIP, and macular volume measures. We hypothesized that patients who had an ever-smoker history would have significantly thinned retina layers compared to patients who were never-smokers. Our results showed no significant differences in the thickness of retinal layers between ever-smoker and never-smoker MS patients.

While cigarette smoking has been consistently associated with MS, the exact mechanism of cigarette smoking toxicity has not been fully understood. The composition of cigarette smoke is complex, comprising more than 7000 chemicals, including nicotine and its derivatives along with a large number of compounds that form the cigarette smoke condensate.^[@bibr18-2055217319828400]^ According to both experimental and epidemiological studies, it is the smoke condensate rather than nicotine that is responsible for the major toxic effects on MS patients.^[@bibr19-2055217319828400],[@bibr20-2055217319828400]^ Some of these toxic compounds can directly damage axons (e.g. nitric oxide) and compounds that trigger demyelination (e.g. cyanates).^[@bibr21-2055217319828400]^ Also, cigarette smoke has been implicated in the activation of lung macrophages, which may incite the proinflammatory cascade of MS.^[@bibr20-2055217319828400],[@bibr22-2055217319828400],[@bibr23-2055217319828400]^ Further, microglial activation in the central nervous system (CNS) has also been suggested as an important hub in the process of demyelination.^[@bibr19-2055217319828400]^

We expected smoking to be detrimental to MS patients via either direct retinal toxicity or through proinflammatory activation of the immune system leading to a more active disease phenotype. In fact, smoking has been shown to have deleterious effects on both the retina and the optic nerve in the context of acute macular degeneration, tobacco--alcohol amblyopia, and Cuban epidemic optic neuropathy.^[@bibr24-2055217319828400],[@bibr25-2055217319828400]^ Furthermore, retinal thinning in MS patients can be due to a direct damage of the optic nerve or to a more widespread process of brain atrophy resulting in trans-synaptic retinal thinning: both relapses and brain atrophy can be facilitated by cigarette smoking.^[@bibr4-2055217319828400],[@bibr15-2055217319828400],[@bibr26-2055217319828400][@bibr27-2055217319828400][@bibr28-2055217319828400][@bibr29-2055217319828400]--[@bibr30-2055217319828400]^

To the best of our knowledge via review of available literature in PubMed, this study appears to be the first to address the association of cigarette ever-smokers versus never-smokers MS patients using OCT imaging. In previous studies of healthy individuals, the effects of cigarette smoking on retinal parameters have been inconsistent. While a few studies showed a decrease in RNFL and choroidal thickness in smokers, other studies have failed to replicate those findings.^[@bibr31-2055217319828400][@bibr32-2055217319828400]--[@bibr33-2055217319828400]^ Cigarette smoking has been shown to play a role in increasing RNFL thinning in migraine patients.^[@bibr34-2055217319828400]^ In contrast, our study showed no effect of smoking on RNFL thinning in MS patients.

The strengths of our study were a large patient population, the presence of smokers and non-smokers, and controlling for history of ON. The main limitations of our study were the cross-sectional design, the lack of more quantitative data on smoking history (e.g. pack-year history), the absence of a control population of smokers and non-smokers, and the division between ever-smokers and never-smokers (i.e. not considering the distinction between past and active smokers). In regard to quantitative smoking data, previous studies showed that cigarette smoking becomes a relevant factor past a given dose threshold. By the same token, quitting can reverse at least some of the negative effects of smoking: the date of quitting is likely to be informative.^[@bibr11-2055217319828400],[@bibr35-2055217319828400]^ Therefore, a precise smoking history and pack-year values may be integral to an optimal analysis of the impact of cigarette smoking.

In conclusion, this study suggests that cigarette smoking history may not have an impact on retinal deterioration in MS. The question is likely more complex than currently appreciated. Therefore, longitudinal studies will be crucial to identify how retinal structures and other sites in the CNS are selectively affected by cigarette smoking. Our study suggests that compartments within the CNS respond differentially to neurodegenerative stressors, and that this factor should be accounted for when considering interventional studies using surrogate markers such as retinal measures for neurodegeneration in MS.
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